[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ache Laboratorios Farmaceuticos S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100638331","phase-3-efficacy-and-safety-of-dnn3119026-for-ocular-hypertension-or-primary-open-angle-glaucoma-100638331",false,"NCT07617532","Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma","A Randomized Clinical Trial to Evaluate the Safety and Efficacy of DNN.31.19.026 for the Treatment of Ocular Hypertension or Primary Open-Angle Glaucoma","RENOIR","Inclusion Criteria:\n\n* Participants of either sex, aged ≥18 years;\n* Participants diagnosed with ocular hypertension or primary open-angle glaucoma according to the Clinical Protocol and Therapeutic Guidelines for Glaucoma;\n* Participants requiring ocular hypotensive treatment in one or both eyes, for whom the use of combination topical ocular hypotensive medications is appropriate for intraocular pressure (IOP) reduction.\n\nExclusion Criteria:\n\n* Participants diagnosed with primary open-angle glaucoma with no prior treatment history for the disease;\n* Participants with a cup-to-disc ratio \\>0.8 (horizontal or vertical);\n* Participants with any other clinically significant ocular disease that, in the investigator's opinion, may interfere with the evaluation of study efficacy and safety variables;\n* Participants with ocular infection or inflammation within 3 months prior to the screening\u002Frun-in visit;\n* Participants with a history of trabeculoplasty (within the last 6 months) or surgical procedures for IOP reduction;\n* Participants with a history of ocular surgery within 6 months prior to the screening\u002Frun-in visit;\n* Participants with any corneal abnormality that may affect IOP measurement;\n* Participants with respiratory or pulmonary disorders, such as asthma or chronic obstructive pulmonary disease (COPD);\n* Participants with the following cardiac conditions: sinus bradycardia, sinoatrial block, second- or third-degree atrioventricular block, overt heart failure, or cardiogenic shock;\n* Participants with uncontrolled systemic diseases, such as diabetes, hypertension, chronic hepatic or renal disorders, or any other medical condition that, in the investigator's opinion, may interfere with the investigational product or comparator.","ALL","18 Years",{"count":20,"type":21},336,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study aims to evaluate the safety and efficacy of DNN.31.19.026 compared with Cosopt® for the treatment of ocular hypertension or primary open-angle glaucoma.",[27,28],"Ocular Hypertension","Primary Open Angle Glaucoma","NOT_YET_RECRUITING","2026-05-25",{"date":32,"type":33},"2026-06-01","ACTUAL",{"date":35,"type":21},"2026-06",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"Ache Laboratorios Farmaceuticos S.A.","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100613733","phase-3-efficacy-safety-of-product-dnn6521005-in-patients-with-benign-prostatic-hyperplasia-100613733","NCT07270432","Efficacy\u002F Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia","Randomized Clinical Trial to Evaluate the Safety and Efficacy of Product DNN.65.21.005 in Alleviating Lower Urinary Tract Symptoms in Patients With Benign Prostatic Hyperplasia","NICCOLO","Inclusion Criteria:\n\n* Male participants aged 50 years and older.\n* Ability to understand the study and provide informed consent, documented by signing the Informed Consent Form (ICF).\n* Participants presenting lower urinary tract symptoms (LUTS) associated with prostate enlargement, without neurological or infectious causes.\n\nExclusion Criteria:\n\n* History or evidence of prostate cancer.\n* Urinary retention ≥100 mL, as assessed by abdominal prostate ultrasound.\n* Previous diagnosis of Parkinson's disease or other neurological disorders that may lead to neurogenic bladder.\n* Use of herbal treatments for prostate enlargement within 14 days prior to the screening visit.\n* Current use or use of alpha-blocker medications within 7 days prior to the start of study treatment.\n* Current use or use of 5-alpha reductase inhibitors (5ARIs) within 180 days prior to the start of study treatment.\n* Use of any prohibited medications within the timeframe specified in the study protocol.\n* Any clinical findings or observations (clinical or physical evaluation) that, in the investigator's judgment, pose a risk to participation in the study.","MALE","50 Years",{"count":52,"type":21},218,[24],"To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia",[56],"Prostatic Hyperplasia, Benign","2025-11-26",{"date":59,"type":33},"2025-12-08",{"date":61,"type":21},"2026-01",{"date":63,"type":21},"2027-04",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100560433","phase-3-efficacy-safety-of-product-cm9241gru-in-patients-with-perennial-allergic-rhinitis-100560433","NCT06577077","Efficacy\u002F Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis","Randomized Clinical Trial to Evaluate the Efficacy and Safety of Product CM9241GRU in Relieving Nasal Symptoms in Perennial Allergic Rhinitis","RESPIRE","Inclusion Criteria:\n\n* Participants of both sexes aged 18 and over\n* Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF)\n* Participants with a diagnosis of perennial allergic rhinitis, as determined by a history of symptoms related to non-seasonal allergen exposure for at least 9 months in the 12 months prior to the screening visit.\n\nExclusion Criteria:\n\n* Participants who have had nasal surgery in the six (6) months prior to the screening visit, or who have obvious external structural abnormalities that interfere with nasal airflow and are considered clinically relevant by the investigator;\n* Participants with non-allergic rhinitis (e.g. vasomotor, infectious, medication or drug-induced rhinitis) or seasonal allergic rhinitis;\n* Participants with a current diagnosis or history of chronic rhinosinusitis, chronic purulent postnasal drip in the two (2) years prior to the screening visit;\n* Participants diagnosed with asthma requiring regular use of systemic or inhaled corticosteroids; uncontrolled asthma (ACT: 5-15); partially controlled asthma (ACT: 16-19);\n* Participants with a history of immunotherapy treatment in the 2 years prior to the screening visit;\n* Participants with an upper respiratory tract infection or rhinosinusitis requiring antibiotic treatment in the 14 days prior to the screening visit and the randomization visit;\n* Participants with an upper respiratory tract viral infection in the 7 days prior to the screening and randomization visits;\n* Participants with severe hypertension, severe coronary artery disease, arrhythmias, glaucoma, hyperthyroidism, prostatic hypertrophy.",{"count":74,"type":21},432,[24],"To evaluate the efficacy and safety of CM9241GRU versus placebo in the treatment of perennial allergic rhinitis.",[78],"Rhinitis, Allergic, Perennial","2024-08-27",{"date":81,"type":33},"2024-08-29",{"date":83,"type":21},"2024-09",{"date":85,"type":21},"2025-08",{"name":39,"class":40},""]